Cytokinetics (CYTK) Metrics: History & Chart

Cytokinetics, Incorporated(CYTK)

Biotechnology · South San Francisco, CA

$61.64-1.06 (-1.69%)

Delayed quote: Oct 6, 2026, 11:10 AM EDT

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

South San Francisco, CA

673 employees

www.cytokinetics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert I. Blum

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-5.23%
30D Total Return	-13.78%
YTD Total Return	-1.32%
1Y Total Return	+10.06%
3Y Total Return	+128.27%
5Y Total Return	+70.32%
10Y Total Return	+569.80%
15Y Total Return	+832.66%
20Y Total Return	+56.36%

2026	-1.32%
2025	+35.08%
2024	-43.66%
2023	+82.21%
2022	+0.53%
2021	+119.35%
2020

CAGR TTM	+10.01%
CAGR 3Y	+31.66%
CAGR 5Y	+11.24%
CAGR 10Y	+20.95%
CAGR 15Y	+16.05%
CAGR 20Y	+2.26%

PE Ratio	52.50
PE Ratio Avg TTM	42.65
PE Ratio Avg 3Y	42.65
Current VS TTM Avg	+23.08%
Current VS 3Y Avg	+23.08%
Current VS 5Y Avg	+23.08%

All Metrics

CYTK Valuation Metrics

CYTK Stock Price Metrics

CYTK Dividend Metrics

CYTK Growth Rate Metrics

CYTK Discounted Cash Flow Metrics

CYTK Returns By Period

CYTK Yearly Returns

CYTK Average Annual Returns By Period (CAGR)

CYTK Revenue Metrics

CYTK PE Ratio Metrics

CYTK PS Ratio Metrics

CYTK PB Ratio Metrics

CYTK Price to Free Cash Flow Ratio Metrics

CYTK Debt to Equity Ratio Metrics

CYTK PEG Ratio Metrics

CYTK FCF Yield

CYTK Earnings Yield

CYTK EBITDA Yield

CYTK OCF Yield

CYTK EV/EBIT Ratio Metrics

CYTK EV/EBITDA Ratio Metrics

CYTK EV/Assets Ratio Metrics

CYTK EV/Sales Ratio Metrics

CYTK Current Ratio Metrics

CYTK Quick Ratio Metrics

CYTK ROIC Metrics

CYTK Return on Assets Metrics

CYTK Return on Equity Metrics

CYTK Net Profit Margin Metrics

CYTK Gross Profit Margin Metrics

CYTK Tax Rate Metrics

PS Ratio	116.71
PS Ratio Avg TTM	88.66
PS Ratio Avg 3Y	675.32
Current VS TTM Avg	+31.64%
Current VS 3Y Avg	-82.72%
Current VS 5Y Avg	-25.94%

PB Ratio	56.19
PB Ratio Avg TTM	54.92
PB Ratio Avg 3Y	29.75
Current VS TTM Avg	+2.32%
Current VS 3Y Avg	+88.85%
Current VS 5Y Avg	+128.95%

PFCF Ratio	61.31
PFCF Ratio Avg TTM	34.85
PFCF Ratio Avg 3Y	44.33
Current VS TTM Avg	+75.95%
Current VS 3Y Avg	+38.29%
Current VS 5Y Avg	+38.29%

Debt/Equity Ratio	(7.32)
Debt/Equity Ratio Avg TTM	(3.09)
Debt/Equity Ratio Avg 3Y	(2.10)
Current VS TTM Avg	-136.96%
Current VS 3Y Avg	-248.45%
Current VS 5Y Avg	-385.37%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.63%
FCF Yield Avg TTM	4.15%
FCF Yield Avg 3Y	2.70%
Current VS TTM Avg	-60.77%
Current VS 3Y Avg	-39.65%
Current VS 5Y Avg	-39.65%

Earnings Yield	1.90%
Earnings Yield Avg TTM	2.33%
Earnings Yield Avg 3Y	2.33%
Current VS TTM Avg	-18.32%
Current VS 3Y Avg	-18.32%
Current VS 5Y Avg	-18.32%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	88.54
Ev/Ebit Ratio Avg TTM	68.93
Ev/Ebit Ratio Avg 3Y	68.93
Current VS TTM Avg	+28.45%
Current VS 3Y Avg	+28.45%
Current VS 5Y Avg	+28.45%

Ev/Ebitda Ratio	75.83
Ev/Ebitda Ratio Avg TTM	60.30
Ev/Ebitda Ratio Avg 3Y	60.30
Current VS TTM Avg	+25.75%
Current VS 3Y Avg	+25.75%
Current VS 5Y Avg	+25.75%

Ev/Assets Ratio	4.83
Ev/Assets Ratio Avg TTM	6.66
Ev/Assets Ratio Avg 3Y	6.12
Current VS TTM Avg	-27.45%
Current VS 3Y Avg	-21.08%
Current VS 5Y Avg	-7.04%

Ev/Sales Ratio	131.02
Ev/Sales Ratio Avg TTM	100.04
Ev/Sales Ratio Avg 3Y	754.35
Current VS TTM Avg	+30.96%
Current VS 3Y Avg	-82.63%
Current VS 5Y Avg	-37.54%

Current Ratio	6.66
Current Ratio Avg TTM	5.81
Current Ratio Avg 3Y	6.39
Current VS TTM Avg	+14.67%
Current VS 3Y Avg	+4.24%
Current VS 5Y Avg	-11.55%

Quick Ratio	6.66
Quick Ratio Avg TTM	5.81
Quick Ratio Avg 3Y	6.39
Current VS TTM Avg	+14.64%
Current VS 3Y Avg	+4.21%
Current VS 5Y Avg	-11.58%

ROIC	(39.80%)
ROIC Avg 3Y	(52.72%)
ROIC Avg 5Y	(43.65%)
Current VS 3Y Avg	+24.51%
Current VS 5Y Avg	+8.82%
Current VS 10Y Avg	-4.28%

ROA	(46.45%)
ROA Avg TTM	(14.33%)
ROA Avg 3Y	(14.08%)
Current VS TTM Avg	-224.23%
Current VS 3Y Avg	-229.89%
Current VS 5Y Avg	-273.28%

ROE	N/A
ROE Avg TTM	N/A
ROE Avg 3Y	(340.42%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(1259.87%)
Net Profit Margin Avg TTM	(3746.88%)
Net Profit Margin Avg 3Y	(11501.97%)
Current VS TTM Avg	+66.38%
Current VS 3Y Avg	+89.05%
Current VS 5Y Avg	+84.73%

Gross Profit Margin	84.97%
Gross Pft Margin Avg TTM	64.23%
Gross Pft Margin Avg 3Y	(5867.53%)
Current VS TTM Avg	+32.28%
Current VS 3Y Avg	+101.45%
Current VS 5Y Avg	+103.47%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.00%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A